???global.info.a_carregar???
Summary: Rita Teixeira de Sousa obtained her Integrated Masters in Medicine from the Faculdade de Medicina de Lisboa in 2008. She specialised in Medical Oncology at the Centro Hospitalar Lisboa Norte during the period from 2010 to 2014. Since April 2015 she has been a Hospital Assistant at the Medical Oncology service of the CHLN. She is coordinator of Medical Oncology at the Clinical Research Centre of Santa Maria Hospital. She also works at the Medical Oncology Service of the Hospital dos Lusíadas Lisboa. Her areas of interest are breast cancer, malignant melanoma and gynaecological tumours. She is an Invited Assistant Professor of Oncobiology and Clinical Oncology at the Faculty of Medicine of the University of Lisbon. She also collaborates with the applied oncology research unit at the Institute of Molecular Medicine, collaborating on several Translational Science projects in the area of biomarkers with special emphasis on Malignant Melanoma and Breast tumours. She obtained Certification by the European Society of Oncology (ESMO) in 2015, becoming a member of ASCO ("American Society of Clinical Oncology"), ESMO ("European Society of Medical Oncologists") and SPO (Portuguese Society of Oncology). She actively collaborates as co-investigator and principal investigator in several international clinical trials. Sumário: Rita Teixeira de Sousa obteve o Mestrado Integrado em Medicina pela Faculdade de Medicina de Lisboa desde 2008. Realizou especialidade de Oncologia Médica no Centro Hospitalar Lisboa Norte durante o período de 2010 a 2014. Desde Abril de 2015 é assistente hospitalar no serviço de oncologia médica do CHLN. É coordenadora da Oncologia Médica do Centro de Investigação Clínica do Hospital de Santa Maria. Exerce ainda funções no Serviço de Oncologia Médica do Hospital dos Lusíadas. Tem como áreas de interesse cancro da mama, melanoma maligno e tumores ginecológicos. É Assistente Convidada das Disciplinas de Oncobiologia e Oncologia Clínica da Faculdade de Medicina da Universidade de Lisboa. Colabora ainda com a unidade de investigação aplicada em oncologia no Instituto de Medicina Molecular, colaborando em vários projectos de Ciência Translacional na área de biomarcadores com especial ênfase no Melanoma Maligno e tumores da Mama. Obteve a Certificação pela Sociedade Europeia de Oncologia (ESMO) em 2015, sendo membro da ASCO ("American Society of Clinical Oncology"), ESMO ("European Society of Medical Oncologists") e SPO (Sociedade Portuguesa de Oncologia). Colabora activamente como co-investigadora e investigadora principal em diversos ensaios clínicos internacionais.
Read full resume ↓
Identification

Personal identification

Full name
Rita Teixeira de Sousa

Citation names

  • Sousa, Rita Teixeira de
  • Sousa, A. R.
  • Rita Sousa
  • Sousa, Rita
  • Sousa, R.

Author identifiers

Ciência ID
A81D-84E4-6399
ORCID iD
0000-0002-9147-7896

Knowledge fields

  • Medical and Health Sciences - Clinical Medicine - Oncology

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Spanish; Castilian Upper intermediate (B2) Upper intermediate (B2) Upper intermediate (B2) Upper intermediate (B2) Upper intermediate (B2)
French Intermediate (B1) Intermediate (B1) Intermediate (B1) Intermediate (B1) Intermediate (B1)
Education
Degree Classification
2018 - 2018
Concluded
 Título Experto en Inmuno-Oncología (Postgraduate Certificate)
Universidad de Navarra, Spain
2018 - 2018
Concluded
 28º Programa de Alta Direcção de Instituições de Saúde (PADIS) (Outros)
AESE Business School, Portugal
2010/01/04 - 2014/12/28
Concluded
 Internato Complementar (Título de especialista)
Major in Oncologia Médica
Centro Hospitalar Universitário Lisboa Norte EPE, Portugal
 19 valores
2014 - 2014
Concluded
 Clinical Scholars Research Training II (CSRT) Certificate Program (Outros)
Fundação para a Ciência e a Tecnologia, Portugal
2013 - 2013
Concluded
 Clinical Scholars Research Training I (CSRT) Certificate Program. (Outros)
Fundação para a Ciência e a Tecnologia, Portugal
2013 - 2013
Concluded
 XXVIII Cours de Chimiothérapie Antitumural et Traitment Médical du Cancer (Postgraduate Certificate)
Institut Gustave Roussy Département de Médecine Oncologique, France
2008/07/23
Concluded
 Medicina (Mestrado integrado)
Major in Medicina
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
 15,48 valores
2002 - 2008
Concluded
 Medicina (Licenciatura)
Major in Medicina
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
Affiliation

Teaching in Higher Education

Category
Host institution 		Employer
2012 - Current Invited Assistant (University Teacher) Universidade de Lisboa, Portugal

Other Careers

Category
Host institution 		Employer
2015/10 - Current Assistente (Médica) Centro Hospitalar Universitário Lisboa Norte EPE, Portugal
Hospital de Santa Maria, Portugal
2015/10 - 2024 Assistente graduado (Médica) Hospital Lusíadas Lisboa, Portugal
2013/11 - 2015/10 Assistente (Médica) Hospital Lusíadas Lisboa, Portugal
2013/12 - 2014/02 Interno (Médica) Guy's and St Thomas' NHS Foundation Trust, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, United Kingdom
2010/01 - 2010/12 Interno (Médica) Hospital de Santa Maria, Portugal
Hospital de Santa Maria, Portugal

Others

Category
Host institution 		Employer
2021/04 - Current Coordinator of Medical Oncology at the Clinical Research Center Hospital de Santa Maria, Portugal
Projects

Other

Designation Funders
2021/10 - Current Multidimensional cartography of healthy, pre-malignant and malignant breast tissues- iMM-Laço Hub
Award
Oncology Consultant
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal
Ongoing
2020 - Current PROGNOSIS OF BREAST CANCER ASSOCIATED WITH THE PORTUGUESE BRCA2 FOUNDER MUTATION c.156_157insAlu
958545
Researcher
Sociedade Portuguesa de Oncologia, Portugal
2019 - Current ONCODYNAMICS BioBanKing: A Holistic Perspective Toward Precision Medicine in Cancer
FPJ000900
Co-investigador
Hospital de Santa Maria, Portugal

Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

International Iberian Nanotechnology Laboratory, Portugal
2018 - Current Multi-Cancer Profile Project (MCPP)
1235215
Co-investigador
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Hospital de Santa Maria, Portugal
2017 - Current Multidisciplinary approach to early detection of cardiotoxicity of oncologic treatment for Breast Cancer.
18548
Researcher
Hospital de Santa Maria, Portugal
2017 - Current PADOC - Estudo de Prevalência de Mutações BRCA em Doentes Portuguesas com Cancro do Ovário, Trompa de Falópio ou Carcinoma Peritoneal Primário com histologia epitelial, não mucinosa
584685
Researcher
Hospital de Santa Maria, Portugal
2016 - Current Papel dos biomarcadores e das técnicas ecocardiográficas no diagnóstico precoce,estratificação de risco e estratégias de prevenção de lesão cardíaca em doentes com neoplasia da mama submetidas a terapêuticas oncológicas.
554485
Researcher
Hospital de Santa Maria, Portugal
Outputs

Publications

Book chapter
  1. "'Diagnosis and management of toxicities associated with immunotherapy in cancer'.". In Handbook od Cancer and Immunology.. 2022.
    Accepted
  2. "'Alternativas para cancro da mama triplo negativo metastático'. Challenging Topics no Cancro da Mama Triplo Negativo". 2022.
    Accepted
  3. Sousa, Rita Teixeira de; Mansinho, André; Lorigan, Paul. "'Melanoma Chapter - ESMO Handbook of Immuno-Oncology'". In ESMO Handbook of Immuno-Oncology, edited by ESMO. Lugano, 2018.
    Published
  4. "Melanoma Maligno - avaliação comparativa de guidelines internacionais". In Melanoma 2013. 2014.
Journal article
  1. Abreu, Catarina; Corredeira, Patricia; Cavaco, Ana; Szeneszi, Lisiana Wachholz; Barradas, Ana; Luis, Henrique; Antunes, Marilia; et al. "Unique Peripheral Immune Profile in Young Women with Metastatic Breast Cancer". Journal of Young Women’s Breast Cancer and Health 1 1&2 (2024): 42-50. https://doi.org/10.4103/ywbc.ywbc_8_24.
    Published • 10.4103/ywbc.ywbc_8_24
  2. Sousa, Rita Teixeira de. "Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer". ESMO Open 8 4 (2023): https://www.sciencedirect.com/science/article/pii/S2059702923008505?dgcid=author.
  3. Sousa, Rita Teixeira de. "Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities". Cancers (2023): https://doi.org/10.3390/cancers15153933 (registering DOI).
    Published
  4. de Pinho, Inês Soares; Luz, Paulo; Alves, Lucy; Lopes-Brás, Raquel; Patel, Vanessa; Esperança-Martins, Miguel; Gonçalves, Lisa; et al. "Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence". Clinical Drug Investigation (2023): http://dx.doi.org/10.1007/s40261-023-01291-6.
    Published • 10.1007/s40261-023-01291-6
  5. Gomes, Inês; Gallego-Paez, Lina M.; Jiménez, Maria; Santamaria, Patricia G.; Mansinho, André; Sousa, Rita Teixeira de; Abreu, Catarina; et al. "Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer". Cell Reports Medicine (2023): https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00248-3.
    10.1016/j.xcrm.2023.101120
  6. Costa, Luís; Alexandre, Teresa; Mansinho, André; Sousa, Rita Teixeira de; Vieira, Cláudia; Hughes, Robert; Roediger, Alexander; Pereira, Sónia Matos; Araújo, António. "Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal". Frontiers in Public Health 11 (2023): http://dx.doi.org/10.3389/fpubh.2023.1133959.
    10.3389/fpubh.2023.1133959
  7. Viale, Giuseppe; Basik, Mark; Niikura, Naoki; Tokunaga, Eriko; Brucker, Sara; Penault-Llorca, Frédérique; Hayashi, Naoki; et al. "Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer". Cancer Research 83 5_Suppleme (2023): HER2-15. http://dx.doi.org/10.1158/1538-7445.sabcs22-her2-15.
    Published • 10.1158/1538-7445.sabcs22-her2-15
  8. Silveira, Catarina; Sousa, Ana Carla; Corredeira, Patrícia; Martins, Marta; Sousa, Rita Teixeira de; Da Cruz Paula, Arnaud; Selenica, Pier; et al. "Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer". Biomolecules 12 12 (2022): 1818. http://dx.doi.org/10.3390/biom12121818.
    Published • 10.3390/biom12121818
  9. Goncalves, L.; Gonçalves, D.; Esteban Casanelles, T.; Soares de Pinho, I.; Barroso, T.; Patel, V.; Esperanca-Martins, M.; et al. "100P Immunotherapy around the clock: Impact on stage IV melanoma". Immuno-Oncology and Technology 16 (2022): 100204. http://dx.doi.org/10.1016/j.iotech.2022.100204.
    Published • 10.1016/j.iotech.2022.100204
  10. Tripathy, Debu; Tolaney, Sara M.; Seidman, Andrew D.; Anders, Carey K.; Ibrahim, Nuhad; Rugo, Hope S.; Twelves, Chris; et al. "Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases". JAMA Oncology 8 7 (2022): 1047. http://dx.doi.org/10.1001/jamaoncol.2022.0514.
    10.1001/jamaoncol.2022.0514
  11. de Pinho, Inês Soares; Abreu, Catarina; Gomes, Inês; Casimiro, Sandra; Pacheco, Teresa Raquel; Sousa, Rita Teixeira de; Costa, Luís. "Exploring new pathways in endocrine-resistant breast cancer". Exploration of Targeted Anti-tumor Therapy (2022): 337-361. http://dx.doi.org/10.37349/etat.2022.00086.
    Published • 10.37349/etat.2022.00086
  12. Schmid, Peter; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kümmel, Sherko; Bergh, Jonas; et al. "Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer". New England Journal of Medicine 386 6 (2022): 556-567. http://dx.doi.org/10.1056/nejmoa2112651.
    10.1056/nejmoa2112651
  13. Paulo Luz ; Isabel Fernandes; Joana Magalhães; Pedro Faísca; João G. Costa; Ana S. Fernandes. "Tumor-infiltrating lymphocytes in early breast cancer: an exploratory analysis focused on HER2+ subtype in Portuguese patients". JBUON (2022):
    Accepted
  14. Luna Pais, Helena; Luz, Paulo; Lobo-Martins, Soraia; Mansinho, André; Sousa, Rita; Luís, Rita; Presa, Dolores; et al. "Immunotherapy in Metastatic Mucosal Melanoma with Disseminated Intravascular Coagulation: A Case of Success". Case Reports in Immunology 2021 (2021): 1-5. http://dx.doi.org/10.1155/2021/5516004.
    Open access • Published • 10.1155/2021/5516004
  15. "Abstract PS17-37: Immune cell populations in peripheral blood of metastatic breast cancer patients under CDK4/6 inhibitors". American Association for Cancer Research 81 4 (2021): 17-37. https://doi.org/10.1158/1538-7445.SABCS20-PS17-37.
    Published
  16. Sousa, Rita Teixeira de; Mansinho, André; Luís Costa; L Soares-de-Almeida; Luna Pais, Helena; Lobo-Martins, Soraia. "BRAF L597K mutation: an opportunity to treat". Dermatology Online Journal (2021): https://escholarship.org/uc/item/18k3573s.
    Published
  17. Bravo, A.C.; Lobo-Martins, S.L.; Vendrell, I.; Mansinho, A.B.; Melo-Alvim, C.; Hasmucrai, D.; Vilariça, A.S.; et al. "1320P Impact of body mass index (BMI) in non-small cell lung cancer patients treated with anti PD-1 immunotherapy (IO): A retrospective cohort study". Annals of Oncology 31 (2020): S852. http://dx.doi.org/10.1016/j.annonc.2020.08.1634.
    Published • 10.1016/j.annonc.2020.08.1634
  18. Lobo-Martins, S.; Martins, M.; Semedo, P.; Alvim, C.; Pais, H. Luna; Paiva, R.; Pinto, C.; et al. "P-151 The impact of adjuvant chemotherapy regimens in stage II colon cancer (CC) patients". Annals of Oncology 31 (2020): S139. http://dx.doi.org/10.1016/j.annonc.2020.04.233.
    Published • 10.1016/j.annonc.2020.04.233
  19. Schmid, Peter; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kümmel, Sherko; Bergh, Jonas; Denkert, Carsten; et al. "Pembrolizumab for Early Triple-Negative Breast Cancer". New England Journal of Medicine 382 9 (2020): 810-821. http://dx.doi.org/10.1056/nejmoa1910549.
    Open access • Published • 10.1056/nejmoa1910549 • Assistant staff
  20. Sousa, Rita Teixeira de. "Prognostic factors for overall survival in patients with advanced melanoma treated with anti-PD-1 therapy - The Melimmune score". Journal for ImmunoTherapy of Cancer 8 suppl 3 (2020): A1-A559. http://dx.doi.org/10.1136/jitc-2020-SITC2020.0007.
    Published
  21. Lobo Martins, Soraia; Miguel-Semedo, Patrícia; Martins-Branco, Diogo Alexandre; Monteiro, Ana Maria; Moreira, Cecilia Melo Alvim; Pais, Helena; Vendrell, Ines; et al. "Hematological profile: A prognosis tool in melanoma patients treated with immunotherapy.". Journal of Clinical Oncology 37 8_suppl (2019): 135-135. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.135.
    10.1200/jco.2019.37.8_suppl.135
  22. Mansinho, André; Ferreira, Arlindo R.; Casimiro, Sandra; Alho, Irina; Vendrell, Inês; Costa, Ana Lúcia; Sousa, Rita; et al. "Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases". International Journal of Molecular Sciences 20 3 (2019): 695. http://dx.doi.org/10.3390/ijms20030695.
    10.3390/ijms20030695
  23. Ferreira, A.R.; Bettencourt, M.; Alho, I.; Costa, A.L.; Sousa, A.R.; Mansinho, A.; Abreu, C.; et al. "Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases". Journal of Bone Oncology 6 (2017): 16-21. http://dx.doi.org/10.1016/j.jbo.2017.01.002.
    10.1016/j.jbo.2017.01.002
  24. "Towards best patient care through cancer clinical trials - HSM/CHLN Serviço de Oncologia contribution for the unmet need". Investigação Clínica - Do compromisso à ação (Apifarma) (2016):
  25. Fiuza, Manuela; Ribeiro, Leonor; Magalhães, Andreia; Sousa, Ana Rita; Nobre Menezes, Miguel; Jorge, Marília; Costa, Luís; Pinto, Fausto José. "Organização e implementação de uma consulta de cardio-oncologia". Revista Portuguesa de Cardiologia 35 9 (2016): 485-494. http://dx.doi.org/10.1016/j.repc.2016.04.006.
    10.1016/j.repc.2016.04.006
  26. Ferreira, Arlindo; Alho, Irina; Vendrell, Inês; Melo, Marta; Brás, Raquel; Costa, Ana Lúcia; Sousa, Ana Rita; et al. "The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases". Oncotarget 7 27 (2016): 41380-41389. http://dx.doi.org/10.18632/oncotarget.9356.
    Published • 10.18632/oncotarget.9356
  27. Sousa, R.; Cortes, P.; Harries, M.; Papa, S.. "Treatment for metastatic melanoma: A New and Evolving Era". International Journal of Clinical Practice 69 3 (2015): 273-280. http://dx.doi.org/10.1111/ijcp.12583.
    10.1111/ijcp.12583
  28. Costa, Ana Lúcia; Abreu, Catarina; Pacheco, Teresa Raquel; Macedo, Daniela; Sousa, Ana Rita; Pulido, Catarina; Quintela, António; Costa, Luís. "Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors". BioMed Research International 2015 (2015): 1-7. http://dx.doi.org/10.1155/2015/309601.
    Published • 10.1155/2015/309601
  29. Macedo, Daniela; Amaral, Teresa; Fernandes, Isabel; Sousa, Ana Rita; Costa, Ana Lúcia; Távora, Isabel; Quintela, António; Cortes, Paulo; Costa, Luís. "The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012". ISRN Hepatology 2013 (2013): 1-9. http://dx.doi.org/10.1155/2013/702167.
    Published • 10.1155/2013/702167
Newsletter article
  1. Casimiro, Sandra; Ines Gomes; Maria Martelo ; Ruben Vilela; Corredeira, Patrícia; André Mansinho; Sofia Torres ; et al. "RANK pathway inhibition sensitizes triple-negative breast cancer to CDK4/6 inhibitors and enhances immune response", Research Square, 2024, https://doi.org/10.21203/rs.3.rs-5377453/v1  START Lisbon Unidade Local de Saúde de Santa Maria  Unidade Local de Saúde de Santa Maria Rita Sousa Unidade Local de Saúde de Santa Maria Luis Costa .
Newspaper article
  1. I. Soares De Pinho ; D. Simão; M. Roldán Galanares ; R. Lopes-Brás ; V. Patel ; M. Esperança-Martins ; L. Gonçalves ; et al. "Anthracycline versus no anthracycline neoadjuvant therapy for HER2 breast cancer: real world evidence", European Journal of Cancer, 2022, 62, https://doi.org/10.1016/S0959-8049(22)01516-7.
Online resource
  1. Rita Teixeira de Sousa. Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes. 2023. https://pubmed.ncbi.nlm.nih.gov/37626878/.

Other

Other output
  1. Revisão de Consensos Sobre Ginecologia Oncológica. Co-autora na Revisão de Consensos Sobre Ginecologia Oncológica. Secção Portuguesa de Ginecologia Oncológica. Capítulo sobre cancro do ovário.. 2020.
Activities

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2021 - Current Formação Específica de Oncologia Médica
Supervisor
Hospital de Santa Maria, Portugal
2019 - Current Formação específica em Oncologia Médica
Supervisor
Hospital de Santa Maria, Portugal
2016 - 2020 Formação Específica de Oncologia Médica
Supervisor
Hospital de Santa Maria, Portugal

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2013 - Current Invited speaker in 10 International Meetings
2013 - Current Invited speaker in 55 National Meetings

Association member

Society Organization name Role
2018 - Current Membro da direcção do Núcleo de Internos e Jovens Oncologistas da SPO desde 2018 Membro da direcção
2008 - Current Membro da Sociedade Portuguesa de Oncologia (SPO) Membro

Consulting

Activity description Institution / Organization
2016 - Current Participação como Investigadora principal de diversos ensaios de fase II e fase IIIB, a destacar a implementação dos dois primeiros ensaios de fase I do serviço. Melanoma: MASTERKEY-265 (NCT02263508); COMBI-I (NCT02967692) Neoplasia da mama: KEYNOTE 522 (NCT03036488); VIOLETTE (NCT03330847); Nektar Attain - 15-102- 14 (NCT02915744); Neoplasias do ovário: PADOC: Estudo de Prevalência de Mutações BRCA em Doentes portuguesas com Cancro do Ovário, trompa de Falópio ou Carcinoma peritoneal primário com histologia epitelial, não mucinosa. Hospital de Santa Maria, Portugal
2016 - Current Participação como Co-investigadora nos seguintes ensaios: Melanoma: COLUMBUS (NCT01909453); NEMO (NCT01763164); BRIM 8 (NCT01667419); CA045001 (NCT03635983); NEKTAR PIVOT12 (NCT04410445) Breast Cancer: SAMANTHA (NCT02913456); Bolero 4 (NCT01698918); TEMPOBreast-01 (EUDRA CT 2014-003860-19); SOPHIA: (NCT02492711); MetaPHer (NCT02402712); BROCADE (NCT02163694); PERUSE (NCT01572038); Berenice (NCT02132949); TnAcity (NCT01881230); MK3475-756 (NCT03725059); CAPitello 290 (NCT03997123); IMpassion 132 (NCT03371017); INAVO120 (NCT04191499); entre outros Hospital de Santa Maria, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2021 - 2021 Virtual IV Postgraduate Update Course in Cardio-Oncology, 2021 (Pós-Graduação)
2020 - 2020 III Curso Pós Graduado de Actualização de Cardio-Oncologia, 2020 (Pós-Graduação)
2019 - 2019 II Curso Pós-Graduado de Atualização Cardio-Oncologia, 2019 (Pós-Graduação)
2018 - 2018 I Curso Pós-Graduado de Atualização Cardio-Oncologia, 2018